Tag
research
45 posts tagged “research”.
Orforglipron: A Tracking Guide for an Oral Small-Molecule GLP-1
A measured, harm-reduction look at orforglipron, a non-peptide GLP-1 pill approved for obesity, and what actually matters to track.
MK-677 (Ibutamoren): A Tracking Guide for an Oral GH Secretagogue
A measured, harm-reduction look at MK-677, what it actually does to GH and IGF-1, and the daily signals and bloodwork worth watching.
Oral Semaglutide 25 mg: A Tracking Guide for the Wegovy Pill
A neutral, harm-reduction guide to the oral semaglutide weight-management pill, its strict dosing rules, and what to monitor.
Ostarine (MK-2866): A Tracking Guide for the Most-Studied SARM
A neutral, harm-reduction look at ostarine, why it is the mildest of the SARMs, and what to monitor given it still suppresses natural hormones.
CagriSema: A Tracking Guide for a Cagrilintide and Semaglutide Combination
A harm-reduction look at CagriSema, an investigational amylin-plus-GLP-1 combination not yet approved, and what would be worth tracking.
Ligandrol (LGD-4033): A Tracking Guide for a Potent Mass-Building SARM
A harm-reduction look at ligandrol, why its strength comes with strong hormonal suppression, and the monitoring that actually matters.
Mazdutide: A Tracking Guide for a Glucagon and GLP-1 Dual Agonist
A neutral, harm-reduction guide to mazdutide, a dual glucagon/GLP-1 agonist approved in China, and what to monitor.
RAD-140 (Testolone): A Tracking Guide for a Strong Lean-Mass SARM
A harm-reduction look at RAD-140, its strong anabolic effect, the reported liver-injury signals, and what to monitor closely.
Survodutide: A Tracking Guide for a GLP-1 and Glucagon Dual Agonist
A harm-reduction look at survodutide, an investigational GLP-1/glucagon agonist with obesity and MASH data, not yet approved.
Cardarine (GW-501516): A Tracking Guide for a PPAR-Delta Agonist
A candid, harm-reduction look at cardarine, its endurance and fat-oxidation effects, and the rodent carcinogenicity signal that ended its development.
Amycretin: A Tracking Guide for a GLP-1 and Amylin Agonist
A neutral, harm-reduction guide to amycretin, an investigational GLP-1/amylin agonist in oral and injectable forms, entering Phase 3.
Andarine (S4): A Tracking Guide for an Older Cutting SARM
A harm-reduction look at andarine, its use in cutting phases, and the reversible vision side effect that sets it apart from other SARMs.
VK2735: A Tracking Guide for a GIP and GLP-1 Dual Agonist
A harm-reduction look at VK2735, an investigational GIP/GLP-1 agonist in oral and injectable Phase 3 programs, not yet approved.
YK-11: A Tracking Guide for a Steroidal Myostatin-Claim Compound
A harm-reduction look at YK-11, a steroidal compound sold as a SARM with myostatin-inhibition claims, and why the human evidence is essentially absent.
Pemvidutide: A Tracking Guide for a GLP-1 and Glucagon Agonist
A neutral, harm-reduction guide to pemvidutide, an investigational GLP-1/glucagon agonist noted for lean-mass sparing and MASH data.
Stenabolic (SR9009): A Tracking Guide for a REV-ERB Exercise Mimetic
A harm-reduction look at SR9009, its exercise-mimetic claims, and the poor oral bioavailability that undercuts most real-world use.
Bimagrumab: A Tracking Guide for an Activin Receptor Antibody
A harm-reduction look at bimagrumab, an investigational antibody that lowers fat while preserving or adding muscle, studied with semaglutide.
Enclomiphene: A Tracking Guide for a Fertility-Preserving SERM
A measured, harm-reduction look at enclomiphene, why it is used instead of exogenous testosterone, and the bloodwork that tells you whether it is working.
Superdrol (Methasterone): A Tracking Guide for a Harsh Oral Steroid
A harm-reduction look at methasterone, a potent and markedly hepatotoxic oral steroid, and the monitoring that matters most if someone has already decided to use it.
Cabergoline: A Tracking Guide for a Prolactin-Lowering Dopamine Agonist
A cautious, harm-reduction look at cabergoline, why it is used to manage prolactin, and the cardiac risk that has to be taken seriously.
Halotestin (Fluoxymesterone): A Tracking Guide for a Potent Oral Androgen
A harm-reduction look at fluoxymesterone, a strong oral steroid used pre-competition for strength and aggression, with honest framing of its liver and lipid risks.
Raloxifene: A Tracking Guide for a Gynecomastia-Focused SERM
A measured, harm-reduction look at raloxifene, why it is often preferred for treating gynecomastia, and the clotting risk to watch.
Proviron (Mesterolone): A Tracking Guide for an Oral DHT Derivative
A measured look at mesterolone, a weakly anabolic oral DHT derivative used as an adjunct to lower SHBG and support libido, and what is worth tracking.
Toremifene: A Tracking Guide for a Tamoxifen-Like SERM
A measured, harm-reduction look at toremifene, how it compares to tamoxifen, and what to monitor when it is used for gyno control or PCT.
Trestolone (MENT): A Tracking Guide for a Potent 19-Nor Injectable
A harm-reduction look at trestolone, a very potent nandrolone-like injectable that is strongly suppressive and aromatizes to a potent estrogen, and what to monitor.
Finasteride and Dutasteride: A Tracking Guide for 5-Alpha-Reductase Inhibitors
A balanced, harm-reduction look at finasteride and dutasteride, how they cut DHT for hair loss, and the honest tradeoffs including post-finasteride syndrome.
DHB (Dihydroboldenone): A Tracking Guide for 1-Testosterone
A harm-reduction look at dihydroboldenone, a non-aromatizing injectable anabolic notorious for post-injection pain, and the monitoring worth doing.
Testosterone Undecanoate: A Tracking Guide for Long-Ester and Oral TRT
A measured, harm-reduction look at testosterone undecanoate in both its very long-ester injectable and oral forms, and the bloodwork that actually matters.
Clenbuterol: A Harm-Reduction Tracking Guide for a Beta-2 Agonist
A cautious, harm-reduction look at clenbuterol, a stimulant thermogenic with real cardiac risk, and what to monitor if you have already decided to use it.
T3 (Liothyronine): A Tracking Guide for a Synthetic Thyroid Hormone
A measured look at liothyronine (T3), why it is used for fat loss, and the muscle and cardiac risks that come with suppressing your own thyroid.
Rapamycin (Sirolimus): A Tracking Guide for an mTOR Inhibitor
An evidence-aware look at rapamycin, the headline off-label longevity drug, what the human data actually shows, and what to monitor on intermittent dosing.
Urolithin A: A Tracking Guide for a Mitophagy Activator
An evidence-aware look at urolithin A, a gut-derived metabolite with human muscle and endurance data, sold as a well-tolerated supplement.
Spermidine: A Tracking Guide for a Polyamine Autophagy Inducer
An evidence-aware look at spermidine, a dietary polyamine linked to autophagy and longevity signals, sold as a wheat-germ-derived supplement.
Fisetin: A Tracking Guide for a Flavonoid Senolytic
An evidence-aware look at fisetin, a plant flavonoid used in intermittent senolytic protocols, and why the human data is still mostly preliminary.
DNP (2,4-Dinitrophenol): A Harm-Reduction Tracking Guide for a Dangerous Uncoupler
A blunt harm-reduction guide to DNP, a mitochondrial uncoupler with a narrow margin between fat loss and death, for people who have already obtained it.
Racetams (Piracetam / Aniracetam / Phenylpiracetam): A Tracking Guide for the Foundational Nootropic Class
A measured look at the classic racetam nootropics, how the common variants differ, and how to track whether they do anything for you.
SNAP-8 (Acetyl Octapeptide-3): A Tracking Guide for the Topical Botox-Mimetic Peptide
Why SNAP-8 is a cosmetic ingredient rather than an injectable, and how to track whether it actually softens expression lines.
Matrixyl (Palmitoyl Pentapeptide-4): A Tracking Guide for the Collagen-Signal Peptide
A measured look at Matrixyl, the topical collagen-stimulating peptide, and how to track whether it does anything for your skin.
Follistatin / ACE-031: A Tracking Guide for the Myostatin-Inhibitor Class
A cautious, harm-reduction look at follistatin and ACE-031, why the human evidence is thin, and what to log if you use them anyway.
Dihexa: A Tracking Guide for a Preclinical Nootropic
A measured look at Dihexa, why almost all of the evidence is in animals, and what a careful self-experimenter would actually log.
Cerebrolysin: A Tracking Guide and an Honest Look at the Evidence
What Cerebrolysin is, why the stroke evidence is genuinely mixed, and the metrics worth logging if you use it.
PE-22-28: A Tracking Guide for a Research-Stage Antidepressant Peptide
A spadin analog that targets TREK-1. What the mechanism implies, why it is research-only, and what to log.
P21: Tracking a Speculative CNTF-Derived Research Peptide
What P21 is, why the human evidence is essentially zero, and how to track it honestly if you choose to experiment at all.
KLOW and Other Multi-Peptide Blends: The Attribution Problem
A practical look at proprietary blends like KLOW, and why tracking them honestly means accepting you cannot isolate any one ingredient.
B7-33: A Tracking Guide for a Single-Chain Relaxin Analog
What B7-33 is, why it is studied in fibrosis and cardiac research, and why human tracking is currently very limited.